Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis

By L. Bolondi, S. Sofia, S. Siringo, S. Gaiani, A. Casali, G. Zironi, F. Piscaglia, L. Gramantieri, M. Zanetti, M. Sherman. Gut, 2001

671 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/e3279b9660809cd1a7bc20b0037cb9e8e99b76fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Management of hepatocellular carcinoma: An update (2011, positive): “Ultrasound has been reported to have a sensitivity of between 65% and 80% and specificity greater than 90% when used as a screening test.(16) However, the performance characteristics have not been as well defined in nodular cirrhotic livers undergoing surveillance.”
Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning (2003, background): “Although routine screening of individuals at risk for developing HCC may extend the life of some patients, many are still diagnosed with advanced HCC and have little chance of surviva”
Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis (2014, background): “1% for non-surveillance Liver function Child C cirrhosis $10% cohort [19,25,40,44,47,54,61] 57.”
Hepatocellular carcinoma: a review (2016, background): “35% to 84%, and is operator and equipment dependent; however, studies have reported a specificity >90% when used for screening.(60,61) Small HCC nodules ≤2 cm represented 85% of the lesions that failed to be detected by US.”
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis (2018, background): “8%) were detected at an early stage.(15,20,22,23,27-32,36,39,40,43,46)”
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001, background): “[7] Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al.”
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “European cohort studies and cost-effectiveness analysis further reinforce the benefits of this policy [3,8].”